Guggenheim raised the firm’s price target on Dianthus (DNTH) to $92 from $84 and keeps a Buy rating on the shares. Ahead of the Phase 2 MaGic trial readout of claseprubart in gMG expected in September, the firm believes investors will benchmark claseprubart’s efficacy responses to Zilbrysq Phase 2 results. The firm, which assigns 70% odds for the program to advance to Phase 3, sees greater than 100% upside potential in its “optimal scenario” and about 50% downside in case of outright failure, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Dianthus Therapeutics’ DNTH103: A Promising Complement Inhibitor with Upcoming Catalysts
- Dianthus initiated with an Outperform at William Blair
- Dianthus Therapeutics: Promising Prospects in Autoimmune Complement Inhibitor Market with DNTH103 Advancements
- Optimistic Buy Rating for Dianthus Therapeutics Amidst Promising C1s Inhibition Developments
- Buy Rating for Dianthus Therapeutics: Promising Growth Potential of DNTH103 in Neuromuscular Disease Treatment